Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer
We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS syste...
Saved in:
Published in | Radiation oncology journal Vol. 38; no. 1; pp. 60 - 67 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
The Korean Society for Radiation Oncology
01.03.2020
대한방사선종양학회 |
Subjects | |
Online Access | Get full text |
ISSN | 2234-1900 2234-3156 2234-3164 |
DOI | 10.3857/roj.2020.00066 |
Cover
Abstract | We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer.
Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm.
The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder.
The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer. |
---|---|
AbstractList | Purpose: We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer.
Materials and Methods: Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm.
Results: The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder.
Conclusions: The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer. KCI Citation Count: 0 We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder. The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer. We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer.PURPOSEWe performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer.Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm.MATERIALS AND METHODSPretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm.The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder.RESULTSThe GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder.The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.CONCLUSIONSThe 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer. |
Author | Kang, Jeong Ku Moon, Sun Rock Jeong, Yuri Oh, Jeong Geun Lee, Kang Kyoo |
Author_xml | – sequence: 1 givenname: Yuri surname: Jeong fullname: Jeong, Yuri – sequence: 2 givenname: Jeong Geun surname: Oh fullname: Oh, Jeong Geun – sequence: 3 givenname: Jeong Ku surname: Kang fullname: Kang, Jeong Ku – sequence: 4 givenname: Sun Rock surname: Moon fullname: Moon, Sun Rock – sequence: 5 givenname: Kang Kyoo surname: Lee fullname: Lee, Kang Kyoo |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32229810$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002574012$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp1kkFv1DAQhS1UREvplSPKEQ5ZxnbiJBekqqJQqRISWs6WY09Yt4m92M5K_Qf92XV2lwqQONnyfO-N7TevyYnzDgl5S2HF27r5GPzdigGDFQAI8YKcMcarktNanBz3tAM4JRcx3sHCQC0EvCKnnDHWtRTOyON6ExBLYyd00XqnxsL4iEVA7V1MYdYpn5a9imiKbcAUUKXMpgXLohSsLnYY7GC1WtDCumLnx_lYmryZR5WyWAVdpA0GtX0oBh-ymY8pVwqtnMbwhrwc1Bjx4riekx_Xn9dXX8vbb19uri5vS12xKpU9bYTBqqadUcb0oNlQa-iYxoHWig6cN8hE3UPTMmEo8I5zVAKrVtEeWs7PyYeDrwuDvNdWemX3608v74O8_L6-kZ3oBG9EZj8d2O3cT2h0fnZQo9wGO6nwsFf-XXF2k312sqE0pwDZ4P3RIPhfM8YkJxs1jqNy6OcoWY6RNbwWLKPv_uz13OR3VBlYHQCdPy4GHJ4RCnIZB5nHQS7jIPfjkAXVPwJt0z6jfFc7_k_2BJYgvV0 |
CitedBy_id | crossref_primary_10_1007_s40042_022_00440_y crossref_primary_10_1016_j_ejmp_2021_09_013 crossref_primary_10_1016_j_radmp_2021_06_001 crossref_primary_10_1097_DM_2024_00010 |
Cites_doi | 10.21037/tro.2018.07.01 10.1118/1.3544657 10.1118/1.598248 10.1002/mp.12810 10.18632/oncotarget.12279 10.1016/j.ejmp.2015.03.017 10.1186/s13014-018-1123-x 10.1200/JCO.2010.31.1217 10.1118/1.3514120 10.1016/j.ejmp.2019.04.014 10.1200/JOP.18.00434 10.1016/j.ejmp.2015.05.016 10.1016/j.ejmp.2014.01.003 10.1186/1748-717X-8-140 10.1118/1.3238104 10.1186/s13014-018-0993-2 10.3857/roj.2018.00122 10.1016/j.ejmp.2017.03.001 10.1118/1.3633904 10.1111/iju.14011 10.1118/1.2890085 10.1259/bjr.20140577 10.1118/1.4767763 |
ContentType | Journal Article |
Copyright | Copyright © 2020 The Korean Society for Radiation Oncology 2020 |
Copyright_xml | – notice: Copyright © 2020 The Korean Society for Radiation Oncology 2020 |
DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
DOI | 10.3857/roj.2020.00066 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Pretreatment QA in prostate cancer VMAT |
EISSN | 2234-3156 2234-3164 |
EndPage | 67 |
ExternalDocumentID | oai_kci_go_kr_ARTI_9696376 PMC7113150 32229810 10_3857_roj_2020_00066 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Wonkwang Institute of Clinical Medicine |
GroupedDBID | 5-W 8JR 8XY 9ZL AAKDD AAYXX ABDBF ACUHS ADBBV AEGXH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK EF. GX1 HYE KQ8 M48 OK1 PGMZT RPM ADRAZ KVFHK NPM 7X8 5PM .UV ACYCR |
ID | FETCH-LOGICAL-c424t-b176de4519daddb0c2f5c092cef15a1f337e265b07826d103933ea6e48a1b0833 |
IEDL.DBID | M48 |
ISSN | 2234-1900 |
IngestDate | Tue Nov 21 21:21:55 EST 2023 Thu Aug 21 18:13:41 EDT 2025 Fri Jul 11 15:57:01 EDT 2025 Thu Jan 02 22:59:18 EST 2025 Tue Jul 01 01:32:54 EDT 2025 Thu Apr 24 23:00:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Gamma analysis Intensity-modulated radiotherapy Prostatic neoplasms Acceptance criteria Dose-volume histogram Pretreatment verification |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c424t-b176de4519daddb0c2f5c092cef15a1f337e265b07826d103933ea6e48a1b0833 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
ORCID | 0000-0003-0573-3994 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3857/roj.2020.00066 |
PMID | 32229810 |
PQID | 2385273562 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9696376 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7113150 proquest_miscellaneous_2385273562 pubmed_primary_32229810 crossref_primary_10_3857_roj_2020_00066 crossref_citationtrail_10_3857_roj_2020_00066 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-03-01 |
PublicationDateYYYYMMDD | 2020-03-01 |
PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Radiation oncology journal |
PublicationTitleAlternate | Radiat Oncol J |
PublicationYear | 2020 |
Publisher | The Korean Society for Radiation Oncology 대한방사선종양학회 |
Publisher_xml | – name: The Korean Society for Radiation Oncology – name: 대한방사선종양학회 |
References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref25 ref20 ref22 ref21 Khan (ref3) 2014 ref8 ref7 ref9 ref4 ref6 ref5 |
References_xml | – ident: ref13 doi: 10.21037/tro.2018.07.01 – ident: ref21 doi: 10.1118/1.3544657 – ident: ref6 doi: 10.1118/1.598248 – ident: ref10 doi: 10.1002/mp.12810 – ident: ref15 doi: 10.18632/oncotarget.12279 – ident: ref17 doi: 10.1016/j.ejmp.2015.03.017 – ident: ref20 doi: 10.1186/s13014-018-1123-x – ident: ref2 doi: 10.1200/JCO.2010.31.1217 – ident: ref9 doi: 10.1118/1.3514120 – ident: ref12 doi: 10.1016/j.ejmp.2019.04.014 – ident: ref1 doi: 10.1200/JOP.18.00434 – ident: ref16 doi: 10.1016/j.ejmp.2015.05.016 – ident: ref18 doi: 10.1016/j.ejmp.2014.01.003 – ident: ref14 doi: 10.1186/1748-717X-8-140 – ident: ref8 doi: 10.1118/1.3238104 – ident: ref11 – ident: ref24 doi: 10.1186/s13014-018-0993-2 – ident: ref5 doi: 10.3857/roj.2018.00122 – ident: ref25 doi: 10.1016/j.ejmp.2017.03.001 – year: 2014 ident: ref3 – ident: ref22 doi: 10.1118/1.3633904 – ident: ref4 doi: 10.1111/iju.14011 – ident: ref7 doi: 10.1118/1.2890085 – ident: ref19 doi: 10.1259/bjr.20140577 – ident: ref23 doi: 10.1118/1.4767763 |
SSID | ssj0000605660 |
Score | 2.177114 |
Snippet | We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated... Purpose: We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 60 |
SubjectTerms | Original 방사선과학 |
Title | Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32229810 https://www.proquest.com/docview/2385273562 https://pubmed.ncbi.nlm.nih.gov/PMC7113150 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002574012 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Radiation oncology journal , 2020, 38(1), , pp.60-67 |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2234-3156 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605660 issn: 2234-1900 databaseCode: KQ8 dateStart: 20110101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 2234-3156 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605660 issn: 2234-1900 databaseCode: ABDBF dateStart: 20120901 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2234-3156 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605660 issn: 2234-1900 databaseCode: DIK dateStart: 20090101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2234-3156 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605660 issn: 2234-1900 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 2234-3156 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605660 issn: 2234-1900 databaseCode: 5-W dateStart: 20110101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central (Free e-resource, activated by CARLI) customDbUrl: eissn: 2234-3156 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605660 issn: 2234-1900 databaseCode: RPM dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2234-3156 dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0000605660 issn: 2234-1900 databaseCode: M48 dateStart: 20120901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Nb9QwEB2xRUK9oCK-Au3KICRORknsOJtDVVWIqiCVU1fqzVp_wdKSQHaR2H_Qn90ZO7u0aHvKIY6j-I09b-KZZ4B3yinv0fNxIRrHJVIS3oRK8RAE8nFR2MpRgfPZV3U6lV8uqot_-U_DAC62hnZ0ntS0v_rw9_fqCCf8IUWcEwzo--4HBnol5WihAx3BQ_RKJVn42UD106qMrj4WDaNDlBz9YJ40HLd0sQuPaAOimVBd7S13NWr7sI2J_p9QectDnezB44FasuNkC0_ggW-fwvU5guW5IxH_JMDBXLfwLAbCG_FYTs7MMUo-XCeeUzN8iAT8GZo7ZRRFENm8ZWlJi7d-do4OAMOHccawVM21YsiEsbMuVisxS4bVP4Ppyafzj6d8OH2BW1nKJTdFrZwn9RmHa6DJbRkqmzel9aGoZkUQovalqgxxDOVoR1kIP1NeTmaFQWInnsNO27X-JbBgatPI3OBklxJHadJUdZk7Y4PyhXUuA74eZG0HaXI6IeNKY4hC-GjERxM-OuKTwftN-19JlOPelm8RM31p55p0tOn6rdOXvcZo4bMmZSBcYDN4s4ZU4-SiHZNZ67s_C418hgTqkCNm8CJBvHnh2kIyqO-Av2lAL7x7p51_jwLedVEIJOKv7u3zNezSN6Rct33YQWvwB0h-lmYcrXoc_0rdAIO8BTY |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Three-dimensional+dose+reconstruction-based+pretreatment+dosimetric+verification+in+volumetric+modulated+arc+therapy+for+prostate+cancer&rft.jtitle=Radiation+oncology+journal&rft.au=Jeong%2C+Yuri&rft.au=Oh%2C+Jeong+Geun&rft.au=Kang%2C+Jeong+Ku&rft.au=Moon%2C+Sun+Rock&rft.date=2020-03-01&rft.issn=2234-1900&rft.volume=38&rft.issue=1&rft.spage=60&rft_id=info:doi/10.3857%2Froj.2020.00066&rft_id=info%3Apmid%2F32229810&rft.externalDocID=32229810 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-1900&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-1900&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-1900&client=summon |